The Effects of Glucagon on Hepatic Metabolism

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 14, 2026 Show 5 more changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 428 words
    • Secondary endpoints: 1 to 3
    • Collaborators expanded, about 10 words
    • Study arms: 3 to 5
  2. Trial completedv8
  3. Re-verified, no change to tracked fieldsv7
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 21
    • Study completion date: Dec 31, 2025 to Mar 31, 2026
    • Site details revised
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Sep 2024 to Sep 30, 2025
    • Study completion date: Sep 2024 to Dec 31, 2025
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Sep 30, 2024 to Sep 2024
    • Study completion date: Dec 31, 2024 to Sep 2024
    • Start date changed from estimate of Oct 1, 2022 to Oct 20, 2022
    • Site details revised
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adrian Vella
3 trials monitored
See all monitored trials
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
and 1 more disease
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).
Trial Details
NCT Number NCT05500586
Lead Sponsor Adrian Vella
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Obesity, Type2diabetes, NAFLD
Related terms Fatty Liver, Insulin Resistance, Non-alcoholic Fatty Liver Disease, Obesity
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov